Experienced in Muir-Torre Syndrome

Dr. Boni E. Elewski

Dermatology
University Of Alabama Health Services Foundation, PC
619 19th St S, 
Birmingham, AL 
Accepting New Patients
Experienced in Muir-Torre Syndrome
University Of Alabama Health Services Foundation, PC
619 19th St S, 
Birmingham, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Boni Elewski is a Dermatologist in Birmingham, Alabama. Dr. Elewski is rated as an Experienced provider by MediFind in the treatment of Muir-Torre Syndrome. Her top areas of expertise are Ringworm, Psoriasis, Plaque Psoriasis, and Generalized Pustular Psoriasis (GPP). Dr. Elewski is currently accepting new patients.

Her clinical research consists of co-authoring 170 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Muir-Torre Syndrome.

Specialties
Dermatology
Licenses
Dermatology in AL
Hospital Affiliations
University Of Alabama Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VIVA Health
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION, PC
619 19th St S, Birmingham, AL 35249

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Enrollment Status: Completed
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drug: Metaderm
Study Phase: Phase 4
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis
Enrollment Status: Completed
Publish Date: October 29, 2021
Intervention Type: Drug
Study Phase: Phase 4
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
Dietary Prevention of Photodamage in Skin With Grapes: A Human Clinical Study
Dietary Prevention of Photodamage in Skin With Grapes: A Human Clinical Study
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

170 Total Publications

Lichen planus onset during interleukin 23 blockade for treatment of psoriasis.
Lichen planus onset during interleukin 23 blockade for treatment of psoriasis.
Journal: JAAD case reports
Published: September 15, 2025
Similar Doctors
Advanced in Muir-Torre Syndrome
Dr. Conway C. Huang
Dermatology
Advanced in Muir-Torre Syndrome
Dr. Conway C. Huang
Dermatology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (0.1 miles away)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Conway Huang is a Dermatologist in Birmingham, Alabama. Dr. Huang is rated as a Distinguished provider by MediFind in the treatment of Muir-Torre Syndrome. His top areas of expertise are Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Bowen's Disease, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Huang is currently accepting new patients.

Experienced in Muir-Torre Syndrome
Dr. Sarah C. Hughey
Dermatology
Experienced in Muir-Torre Syndrome
Dr. Sarah C. Hughey
Dermatology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (0.1 miles away)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sarah Hughey is a Dermatologist in Birmingham, Alabama. Dr. Hughey is rated as a Distinguished provider by MediFind in the treatment of Muir-Torre Syndrome. Her top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Melanoma, Mycosis Fungoides, and Ecthyma. Dr. Hughey is currently accepting new patients.

Experienced in Muir-Torre Syndrome
Dr. Malia B. Downing
Dermatology
Experienced in Muir-Torre Syndrome
Dr. Malia B. Downing
Dermatology

Ssd, LLC

48 Medical Park Dr E, Suite 458, 
Birmingham, AL 
 (9.9 miles away)
205-900-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Malia Downing is a Dermatologist in Birmingham, Alabama. Dr. Downing is rated as an Experienced provider by MediFind in the treatment of Muir-Torre Syndrome. Her top areas of expertise are Pyoderma Gangrenosum, Generalized Pustular Psoriasis (GPP), Muir-Torre Syndrome, and Basal Cell Skin Cancer. Dr. Downing is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Elewski's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile